Loading…
for educational and safety purposes
Bromocriptine and Cabergoline both come up in the same conversations; they overlap on dopamine D2 receptors and pituitary. Bromocriptine: Bromocriptine is a dopamine receptor agonist derived from ergot, acting mainly at the dopamine D2 receptor. Cabergoline: Cabergoline is a long-acting, ergot-derived dopamine agonist that acts mainly at the dopamine D2 receptor.
Bromocriptine is a dopamine receptor agonist derived from ergot, acting mainly at the dopamine D2 receptor. It is used to treat conditions linked to excess prolactin, such as prolactinomas and related infertility, as well as Parkinson disease, acromegaly, and, in a quick-release form, type 2 diabetes. Discovered by Sandoz in the 1960s, it was approved for medical use in the 1970s.
Cabergoline is a long-acting, ergot-derived dopamine agonist that acts mainly at the dopamine D2 receptor. It is used chiefly to treat conditions of excess prolactin, especially prolactin-secreting pituitary tumors (prolactinomas), and is also used in Parkinson disease and acromegaly. Because of its long duration of action it is usually taken only once or twice a week.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
agonist
agonist
activates
modulates
antagonist
agonist
agonist
agonist
modulates
agonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.